Ex Vivo Lung Perfusion: A Review of Research and Clinical Practices.
Patrick G ChanAkshay KumarKathirvel SubramaniamPablo G SanchezPublished in: Seminars in cardiothoracic and vascular anesthesia (2020)
End-stage lung disease is ultimately treated with lung transplantation. However, there is a paucity of organs with an increasing number of patients being diagnosed with end-stage lung disease. Ex vivo lung perfusion has emerged as a potential tool to assess the quality and to recondition marginal donor lungs prior to transplantation with the goal of increasing the donor pool. This technology has shown promise with similar results compared with the conventional technique of cold static preservation in terms of primary graft dysfunction and overall outcomes. This review provides an update on the results and uses of this technology. The review will also summarize clinical studies and techniques in reconditioning and assessing lungs on ex vivo lung perfusion. Last, we discuss how this technology can be applied to fields outside of transplantation such as thoracic oncology and bioengineering.
Keyphrases
- end stage renal disease
- newly diagnosed
- contrast enhanced
- healthcare
- chronic kidney disease
- primary care
- cell therapy
- spinal cord
- oxidative stress
- peritoneal dialysis
- extracorporeal membrane oxygenation
- magnetic resonance
- mesenchymal stem cells
- patient reported outcomes
- skeletal muscle
- insulin resistance
- glycemic control